Cargando…

Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial

BACKGROUND: Low-grade serous carcinoma of the ovary or peritoneum is characterised by MAPK pathway aberrations and its reduced sensitivity to chemotherapy relative to high-grade serous carcinoma. We compared the MEK inhibitor trametinib to physician's choice standard of care in patients with re...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gershenson, David M, Miller, Austin, Brady, William E, Paul, James, Carty, Karen, Rodgers, William, Millan, David, Coleman, Robert L, Moore, Kathleen N, Banerjee, Susana, Connolly, Kate, Secord, Angeles Alvarez, O'Malley, David M, Dorigo, Oliver, Gaillard, Stephanie, Gabra, Hani, Slomovitz, Brian, Hanjani, Parviz, Farley, John, Churchman, Michael, Ewing, Ailith, Hollis, Robert L, Herrington, C Simon, Huang, Helen Q, Wenzel, Lari, Gourley, Charlie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8819271/ https://www.ncbi.nlm.nih.gov/pubmed/35123694 http://dx.doi.org/10.1016/S0140-6736(21)02175-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8819271/
https://www.ncbi.nlm.nih.gov/pubmed/35123694
http://dx.doi.org/10.1016/S0140-6736(21)02175-9

Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial

Internet

Ejemplares similares